Filament Health Corp., a clinical-stage natural psychedelic drug development company, and Psyence Group Inc, a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, today announced the conclusion of a royalty-bearing, worldwide commercial licensing agreement. The agreement grants Psyence the worldwide right to commercialize Filament
